Barrett’s esophagus (BE) is the only well-known precursor lesion of esophageal adenocarcinoma (EA). The exact estimates of the annual progression rate from BE to EA vary from 0.07% to 3.6%. The identification of BE patients at higher risk to progress to EA is hence mandatory, although difficult to accomplish. In search of novel BE biomarkers we analyzed the efficacy of hERG1 potassium channels in predicting BE progression to EA. Once tested by immunohistochemistry (IHC) on bioptic samples, hERG1 was expressed in BE, and its expression levels increased during progression from BE to esophageal dysplasia (ED) and EA. hERG1 was also over-expressed in the metaplastic cells arising in BE lesions obtained in different BE mouse models, induced either surgically or chemically. Furthermore, transgenic mice which over express hERG1 in the whole gastrointestinal tract, developed BE lesions after an esophago-jejunal anastomosis more frequently, compared to controls. A case-control study was performed on 104 bioptic samples from newly diagnosed BE patients further followed up for at least 10 years. It emerged a statistically significant association between hERG1 expression status and risk of progression to EA. Finally, a novel fluorophore- conjugated recombinant single chain variable fragment antibody (scFv-hERG1-Alexa488) was tested on freshly collected live BE biopsies: it could recognize hERG1 positive samples, perfectly matching IHC data. Overall, hERG1 can be considered a novel BE biomarker to be exploited for a novel endoscopic surveillance protocol, either in biopsies or through endoscopy, to identify those BE patients with higher risk to progress to EA.

hERG1 behaves as biomarker of progression to adenocarcinoma in Barrett's esophagus and can be exploited for a novel endoscopic surveillance / Lastraioli, Elena; Lottini, Tiziano; Iorio, Jessica; Freschi, Giancarlo; Fazi, Marilena; Duranti, Claudia; Carraresi, Laura; Messerini, Luca; Taddei, Antonio; Ringressi, Maria Novella; Salemme, Marianna; Villanacci, Vincenzo; Vindigni, Carla; Tomezzoli, Anna; La Mendola, Roberta; Bencivenga, Maria; Compagnoni, Bruno; Chiudinelli, Mariella; Saragoni, Luca; Manzi, Ilaria; De Manzoni, Giovanni; Bechi, Paolo; Boni, Luca; Arcangeli, Annarosa. - In: ONCOTARGET. - ISSN 1949-2553. - ELETTRONICO. - 7:(2016), pp. 59535-59547. [10.18632/oncotarget.11149]

hERG1 behaves as biomarker of progression to adenocarcinoma in Barrett's esophagus and can be exploited for a novel endoscopic surveillance

LASTRAIOLI, ELENA;LOTTINI, TIZIANO;IORIO, JESSICA;FRESCHI, GIANCARLO;FAZI, MARILENA;DURANTI, CLAUDIA;CARRARESI, LAURA;MESSERINI, LUCA;TADDEI, ANTONIO;RINGRESSI, MARIA NOVELLA;SARAGONI, LUCA;BECHI, PAOLO;BONI, LUCA;ARCANGELI, ANNAROSA
2016

Abstract

Barrett’s esophagus (BE) is the only well-known precursor lesion of esophageal adenocarcinoma (EA). The exact estimates of the annual progression rate from BE to EA vary from 0.07% to 3.6%. The identification of BE patients at higher risk to progress to EA is hence mandatory, although difficult to accomplish. In search of novel BE biomarkers we analyzed the efficacy of hERG1 potassium channels in predicting BE progression to EA. Once tested by immunohistochemistry (IHC) on bioptic samples, hERG1 was expressed in BE, and its expression levels increased during progression from BE to esophageal dysplasia (ED) and EA. hERG1 was also over-expressed in the metaplastic cells arising in BE lesions obtained in different BE mouse models, induced either surgically or chemically. Furthermore, transgenic mice which over express hERG1 in the whole gastrointestinal tract, developed BE lesions after an esophago-jejunal anastomosis more frequently, compared to controls. A case-control study was performed on 104 bioptic samples from newly diagnosed BE patients further followed up for at least 10 years. It emerged a statistically significant association between hERG1 expression status and risk of progression to EA. Finally, a novel fluorophore- conjugated recombinant single chain variable fragment antibody (scFv-hERG1-Alexa488) was tested on freshly collected live BE biopsies: it could recognize hERG1 positive samples, perfectly matching IHC data. Overall, hERG1 can be considered a novel BE biomarker to be exploited for a novel endoscopic surveillance protocol, either in biopsies or through endoscopy, to identify those BE patients with higher risk to progress to EA.
2016
7
59535
59547
Goal 3: Good health and well-being for people
Lastraioli, Elena; Lottini, Tiziano; Iorio, Jessica; Freschi, Giancarlo; Fazi, Marilena; Duranti, Claudia; Carraresi, Laura; Messerini, Luca; Taddei, Antonio; Ringressi, Maria Novella; Salemme, Marianna; Villanacci, Vincenzo; Vindigni, Carla; Tomezzoli, Anna; La Mendola, Roberta; Bencivenga, Maria; Compagnoni, Bruno; Chiudinelli, Mariella; Saragoni, Luca; Manzi, Ilaria; De Manzoni, Giovanni; Bechi, Paolo; Boni, Luca; Arcangeli, Annarosa
File in questo prodotto:
File Dimensione Formato  
2016 - Oncotarget Barrett.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 5.51 MB
Formato Adobe PDF
5.51 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1067059
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact